
Opinion|Videos|November 8, 2024
Management of Generalized Myasthenia Gravis in Pediatric Patients
Key Takeaways
- Diagnosing pediatric gMG is challenging due to its rarity and symptom overlap with other neuromuscular disorders, necessitating careful clinical evaluation.
- Standard management includes acetylcholinesterase inhibitors, corticosteroids, and immunosuppressants, customized to each patient's needs.
Panelists discuss how generalized myasthenia gravis (gMG) presents unique diagnostic challenges in pediatric populations, review current standard-of-care management strategies for children and adolescents, and highlight promising investigational treatments for pediatric gMG.
Advertisement
Video content above is prompted by the following:
- Generalized MG, although rare, can affect children and adolescents. What are the challenges in diagnosing this patient population?
- What is the standard of care for management of gMG in the pediatric population?
- Please highlight some investigational agents for pediatric gMG that you are excited about.
Newsletter
Keep your finger on the pulse of neurology—subscribe to NeurologyLive for expert interviews, new data, and breakthrough treatment updates.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
Repositioning GLP-1 Drugs for Neurologic Disease: Evidence, Advances, and Outlook
2
CAPN2-Targeting Agent AMX0114 Shows Safe Profile in Phase 1 LUMINA Trial of ALS
3
What the First Intrathecal Gene Therapy Means for SMA Clinicians and Researchers
4
FDA Approves Inebilizumab for Myasthenia Gravis, Phase 3 PREVAiLS Study Launched, Tolebrutinib Fails Phase 3 PERSEUS Study
5



















